Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID
Completed · Phase 3
Conditions studied: Primary Immunodeficiency Disease
In brief
This Phase III clinical study is to test efficacy, safety and pharmacokinetics of BT595 in treating patients with Primary Immunodeficiency (PID)
Key facts
- Study ID
- NCT02810444
- Run by
- Biotest
- People needed
- 81
- Starts
- 2016-10-04
- Expected to finish
- 2020-04-01
- Last updated by the study team
- 2023-07-20
Who can join
Age: 2 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Investigational site # 0104 — Birmingham, Alabama, United States
- Investigational site # 0116 — Los Angeles, California, United States
- Investigational site # 0103 — Centennial, Colorado, United States
- Investigational site # 0114 — Thornton, Colorado, United States
- Investigational site # 0111 — Chicago, Illinois, United States
- Investigational site # 0106 — South Bend, Indiana, United States
- Investigational site # 0105 — Toledo, Ohio, United States
- Investigational site #0115 — Memphis, Tennessee, United States
- Investigational Site # 0102 — Dallas, Texas, United States
- Investigational site # 4902 — Frankfurt am Main, Germany
- Investigational site # 4904 — Freiburg im Breisgau, Germany
- Investigational site #4905 — Leipzig, Germany
- Investigational site # 3602 — Budapest, Hungary
- Investigational Site # 3605 — Miskolc, Hungary
- Investigational site #3603 — Nyíregyháza, Hungary
- Investigational site # 0702 — Moscow, Russia
- Investigational site # 0704 — Yekaterinburg, Russia
- Investigational site # 3403 — Barcelona, Spain
- Investigational site # 3405 — Madrid, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.